Cantor Fitzgerald Expects Reduced Earnings for Zura Bio

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Zura Bio in a report issued on Wednesday, March 26th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($0.45) per share for the year, down from their previous estimate of ($0.40). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

Several other brokerages have also recently weighed in on ZURA. Oppenheimer reaffirmed an “outperform” rating and issued a $19.00 price target (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. Chardan Capital cut their price objective on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Guggenheim reiterated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Zura Bio presently has a consensus rating of “Buy” and an average target price of $15.00.

Zura Bio Stock Performance

NASDAQ ZURA opened at $1.36 on Friday. The business has a 50 day moving average price of $1.47 and a 200-day moving average price of $2.75. Zura Bio has a 52 week low of $1.07 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter.

Hedge Funds Weigh In On Zura Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. purchased a new stake in Zura Bio during the fourth quarter worth about $27,000. Prudential Financial Inc. purchased a new stake in shares of Zura Bio during the 4th quarter worth approximately $28,000. Two Sigma Advisers LP bought a new stake in shares of Zura Bio in the 4th quarter worth approximately $32,000. ProShare Advisors LLC purchased a new position in Zura Bio in the fourth quarter valued at approximately $35,000. Finally, XTX Topco Ltd bought a new position in Zura Bio during the fourth quarter valued at $44,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.